Which has higher earnings and valuation, LYEL or ALMS?

Alumis has higher revenue and earnings than Lyell Immunopharma. Alumis is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lyell Immunopharma $40K 4,599.88 -$274.45M -$12.83 N/A Alumis $24.05M 35.30 -$243.32M -$3.86 N/A

Is LYEL or ALMS more profitable?

Alumis has a net margin of -5,933.46% compared to Lyell Immunopharma's net margin of -920,285.25%. Lyell Immunopharma's return on equity of -91.62% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Lyell Immunopharma -920,285.25% -91.62% -70.50% Alumis -5,933.46% -93.15% -74.50%

Lyell Immunopharma (LYEL) Competitors

$7.98 +0.47 (+6.27%)

As of 03:52 PM Eastern

Compare

LYEL vs. ALMS, RIGL, GLUE, SANA, and ANNX

Should you buy Lyell Immunopharma stock or one of its competitors? Lyell Immunopharma's main competitors and comparable companies include Alumis (ALMS), Rigel Pharmaceuticals (RIGL), Monte Rosa Therapeutics (GLUE), Sana Biotechnology (SANA), and Annexon (ANNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lyell Immunopharma compare to Alumis?

Lyell Immunopharma (NASDAQ:LYEL) and Alumis (NASDAQ:ALMS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Lyell Immunopharma currently has a consensus target price of $40.86, indicating a potential upside of 444.04%. Alumis has a consensus target price of $33.27, indicating a potential upside of 407.21%. Given Lyell Immunopharma's higher probable upside, research analysts clearly believe Lyell Immunopharma is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Alumis	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Lyell Immunopharma has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market. Comparatively, Alumis has a beta of -0.38, suggesting that its share price is 138% less volatile than the broader market.

Alumis has a net margin of -5,933.46% compared to Lyell Immunopharma's net margin of -920,285.25%. Lyell Immunopharma's return on equity of -91.62% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%
Alumis	-5,933.46%	-93.15%	-74.50%

66.1% of Lyell Immunopharma shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 33.7% of Alumis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Alumis had 9 more articles in the media than Lyell Immunopharma. MarketBeat recorded 11 mentions for Alumis and 2 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 0.93 beat Alumis' score of 0.55 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Lyell Immunopharma	Positive
Alumis	Positive

Alumis has higher revenue and earnings than Lyell Immunopharma. Alumis is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	4,599.88	-$274.45M	-$12.83	N/A
Alumis	$24.05M	35.30	-$243.32M	-$3.86	N/A

Summary

Alumis beats Lyell Immunopharma on 8 of the 15 factors compared between the two stocks.

How does Lyell Immunopharma compare to Rigel Pharmaceuticals?

Lyell Immunopharma (NASDAQ:LYEL) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Lyell Immunopharma has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Lyell Immunopharma currently has a consensus target price of $40.86, indicating a potential upside of 444.04%. Rigel Pharmaceuticals has a consensus target price of $59.00, indicating a potential upside of 25.16%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Lyell Immunopharma is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Rigel Pharmaceuticals has a net margin of 116.30% compared to Lyell Immunopharma's net margin of -920,285.25%. Rigel Pharmaceuticals' return on equity of 22.95% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Rigel Pharmaceuticals has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	4,599.88	-$274.45M	-$12.83	N/A
Rigel Pharmaceuticals	$294.28M	2.96	$367.02M	$16.32	2.89

In the previous week, Lyell Immunopharma and Lyell Immunopharma both had 2 articles in the media. Lyell Immunopharma's average media sentiment score of 0.93 beat Rigel Pharmaceuticals' score of 0.89 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Lyell Immunopharma	Positive
Rigel Pharmaceuticals	Positive

Summary

Rigel Pharmaceuticals beats Lyell Immunopharma on 10 of the 16 factors compared between the two stocks.

How does Lyell Immunopharma compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Monte Rosa Therapeutics currently has a consensus price target of $26.67, suggesting a potential upside of 169.63%. Lyell Immunopharma has a consensus price target of $40.86, suggesting a potential upside of 444.04%. Given Lyell Immunopharma's higher probable upside, analysts plainly believe Lyell Immunopharma is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Monte Rosa Therapeutics has a net margin of -560.85% compared to Lyell Immunopharma's net margin of -920,285.25%. Monte Rosa Therapeutics' return on equity of -43.31% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

In the previous week, Monte Rosa Therapeutics had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 4 mentions for Monte Rosa Therapeutics and 2 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 0.93 beat Monte Rosa Therapeutics' score of 0.24 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Monte Rosa Therapeutics	Neutral
Lyell Immunopharma	Positive

Monte Rosa Therapeutics has higher revenue and earnings than Lyell Immunopharma. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	6.82	-$38.63M	-$1.76	N/A
Lyell Immunopharma	$40K	4,599.88	-$274.45M	-$12.83	N/A

Monte Rosa Therapeutics has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

Summary

Monte Rosa Therapeutics beats Lyell Immunopharma on 12 of the 16 factors compared between the two stocks.

How does Lyell Immunopharma compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Sana Biotechnology has higher earnings, but lower revenue than Lyell Immunopharma. Sana Biotechnology is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Lyell Immunopharma	$40K	4,599.88	-$274.45M	-$12.83	N/A

Sana Biotechnology has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market.

Sana Biotechnology has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Lyell Immunopharma's return on equity of -91.62% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

Sana Biotechnology presently has a consensus target price of $9.33, suggesting a potential upside of 287.28%. Lyell Immunopharma has a consensus target price of $40.86, suggesting a potential upside of 444.04%. Given Lyell Immunopharma's higher possible upside, analysts clearly believe Lyell Immunopharma is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Sana Biotechnology had 4 more articles in the media than Lyell Immunopharma. MarketBeat recorded 6 mentions for Sana Biotechnology and 2 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 0.93 beat Sana Biotechnology's score of 0.54 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Sana Biotechnology	Positive
Lyell Immunopharma	Positive

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Sana Biotechnology beats Lyell Immunopharma on 10 of the 15 factors compared between the two stocks.

How does Lyell Immunopharma compare to Annexon?

Lyell Immunopharma (NASDAQ:LYEL) and Annexon (NASDAQ:ANNX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Annexon has lower revenue, but higher earnings than Lyell Immunopharma. Annexon is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	4,599.88	-$274.45M	-$12.83	N/A
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A

66.1% of Lyell Immunopharma shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by company insiders. Comparatively, 10.3% of Annexon shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Annexon has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Lyell Immunopharma's return on equity of -91.62% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%
Annexon	N/A	-106.15%	-79.82%

In the previous week, Lyell Immunopharma and Lyell Immunopharma both had 2 articles in the media. Annexon's average media sentiment score of 1.45 beat Lyell Immunopharma's score of 0.93 indicating that Annexon is being referred to more favorably in the news media.

Company	Overall Sentiment
Lyell Immunopharma	Positive
Annexon	Positive

Lyell Immunopharma has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market. Comparatively, Annexon has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

Lyell Immunopharma currently has a consensus price target of $40.86, suggesting a potential upside of 444.04%. Annexon has a consensus price target of $15.29, suggesting a potential upside of 299.10%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Lyell Immunopharma is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Lyell Immunopharma beats Annexon on 7 of the 13 factors compared between the two stocks.

Get Lyell Immunopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LYEL vs. The Competition

Export

Metric	Lyell Immunopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$197.74M	$3.90B	$7.29B	$12.91B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-0.63	12.96	275.68	25.25
Price / Sales	4,946.55	1,151.37	562.78	78.51
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.69	16.59	10.54	5.92
Net Income	-$274.45M	-$22.69M	$3.50B	$381.16M
7 Day Performance	-5.65%	-6.38%	-4.13%	-4.32%
1 Month Performance	-28.72%	-14.15%	-8.51%	-7.19%
1 Year Performance	-52.10%	6.41%	2.12%	-4.99%

Lyell Immunopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LYEL Lyell Immunopharma	2.6328 of 5 stars	$8.08 +7.5%	$40.86 +405.9%	-55.4%	$197.74M	$40K	N/A	161	High Trading Volume
ALMS Alumis	3.763 of 5 stars	$6.93 +1.3%	$33.27 +380.1%	+42.3%	$885.34M	$24.05M	N/A	239	Options Volume
RIGL Rigel Pharmaceuticals	4.4968 of 5 stars	$46.11 -3.5%	$59.00 +28.0%	+75.7%	$884.21M	$294.28M	2.83	174
GLUE Monte Rosa Therapeutics	2.5801 of 5 stars	$9.87 -3.9%	$27.63 +179.9%	-4.9%	$876.17M	$28.73M	N/A	173	Analyst Upgrade
SANA Sana Biotechnology	3.4066 of 5 stars	$2.75 -4.5%	$9.33 +239.4%	-44.5%	$862.16M	N/A	N/A	142	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LYEL) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lyell Immunopharma (LYEL) Competitors

LYEL vs. ALMS, RIGL, GLUE, SANA, and ANNX

How does Lyell Immunopharma compare to Alumis?

Summary

How does Lyell Immunopharma compare to Rigel Pharmaceuticals?

Summary

How does Lyell Immunopharma compare to Monte Rosa Therapeutics?

Summary

How does Lyell Immunopharma compare to Sana Biotechnology?

Summary

How does Lyell Immunopharma compare to Annexon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lyell Immunopharma (LYEL) Competitors

LYEL vs. ALMS, RIGL, GLUE, SANA, and ANNX

How does Lyell Immunopharma compare to Alumis?

Do analysts recommend LYEL or ALMS?

Which has more volatility & risk, LYEL or ALMS?

Is LYEL or ALMS more profitable?

Do institutionals and insiders believe in LYEL or ALMS?

Does the media refer more to LYEL or ALMS?

Which has higher earnings and valuation, LYEL or ALMS?

Summary

How does Lyell Immunopharma compare to Rigel Pharmaceuticals?

Which has more risk & volatility, LYEL or RIGL?

Do insiders & institutionals believe in LYEL or RIGL?

Do analysts recommend LYEL or RIGL?

Is LYEL or RIGL more profitable?

Which has stronger earnings & valuation, LYEL or RIGL?

Does the media refer more to LYEL or RIGL?

Summary

How does Lyell Immunopharma compare to Monte Rosa Therapeutics?

Do analysts recommend GLUE or LYEL?

Do institutionals and insiders have more ownership in GLUE or LYEL?

Is GLUE or LYEL more profitable?

Does the media favor GLUE or LYEL?

Which has preferable earnings and valuation, GLUE or LYEL?

Which has more volatility & risk, GLUE or LYEL?

Summary

How does Lyell Immunopharma compare to Sana Biotechnology?

Which has stronger valuation and earnings, SANA or LYEL?

Which has more risk and volatility, SANA or LYEL?

Is SANA or LYEL more profitable?

Do analysts recommend SANA or LYEL?

Does the media favor SANA or LYEL?

Do institutionals & insiders have more ownership in SANA or LYEL?

Summary

How does Lyell Immunopharma compare to Annexon?

Which has preferable valuation & earnings, LYEL or ANNX?

Do insiders & institutionals hold more shares of LYEL or ANNX?

Is LYEL or ANNX more profitable?

Does the media prefer LYEL or ANNX?

Which has more volatility and risk, LYEL or ANNX?

Do analysts prefer LYEL or ANNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools